
|Articles|January 6, 2005
TAP Pharmaceutical to settle claims, pay $150 million
TAP Pharmaceutical Products agreed to settle claims that consumers and private insurers overpaid for the LHRH hormone analog leuprolide acetate (Lupron), according to a report in The Boston Globe.
Advertisement
Advertisement
Related Content
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves capivasertib plus abiraterone and prednisone for PTEN-deficient mHSPC
2
Dean Elterman, MD, highlights efficacy and safety data on the Zenflow Prostatic Spring
3
Toni Choueiri, MD, reacts to FDA approval of adjuvant belzutifan with pembrolizumab for ccRCC
4
FDA approves adjuvant belzutifan with pembrolizumab for ccRCC
5










